Increased Oxytocin Doses to be Tested for Reducing C-Section Rates in Obese Primiparous Women

The incidence of caesarean section is notably elevated among obese pregnant women, contributing to increased maternal morbidity within this already vulnerable demographic. Oxytocin is the primary pharmacological agent employed in obstetrics to optimize labor progression. However, existing observational studies suggest that the efficacy of standard oxytocin doses may be insufficient in obese women, potentially contributing to higher intervention rates. This trial aims to address this critical gap by exploring an optimized dosing strategy.

Researchers designed a randomised controlled trial to evaluate the impact of an increased oxytocin dose on the rate of caesarean section. The study population will consist of obese primiparous women experiencing either spontaneous or induced labor. The intervention arm will receive an increased oxytocin dose, while the control arm will likely receive standard oxytocin dosing (implied by the comparison). The primary endpoint for this trial is the overall caesarean section rate, aiming to determine if a higher dose can improve labor outcomes in this specific high-risk group.